Loading company
$5.66-1.7%Nov 13 close
Next earnings: November 24, 2026 · before the open
Figures through March 31, 2026, from the 6-K filed May 13, 2026
Past performance
- 1W
- +2.7%
- 1M
- -4.2%
- 3M
- -20.6%
- 6M
- -0.4%
- 1Y
- -37.5%
- 5Y
- -86.0%
$5.66-1.7%Nov 13 close
Next earnings: November 24, 2026 · before the open
Figures through March 31, 2026, from the 6-K filed May 13, 2026
Valneva SE is scheduled to report next on November 24, 2026, before the open. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $34.2M | $54.4M | -37.23% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Valneva SE has no earnings call transcript available.
SE We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com . Valneva Investor and
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Valneva SE filed on August 13, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.